Overview Dividends

(HOLX) Hologic - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US4364401012

Diagnostics, Medical Imaging, Surgical Products, Womens Health

HOLX EPS (Earnings per Share)

EPS Growth (3Y CAGR): 10.53%
EPS Trend (3Y Correlation): 51.8%

HOLX Revenue

Revenue Growth (3Y CAGR): 2.63%
Revenue Trend (3Y Correlation): 14.0%

Description: HOLX Hologic

Hologic Inc. is a leading player in the healthcare equipment industry, specializing in womens health through early detection and treatment. The company operates through four main segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health, offering a diverse range of products and solutions.

The Diagnostics segment is a key contributor, with a portfolio of molecular diagnostic assays, including Aptima and Panther Fusion, which detect infectious microorganisms and viruses, such as SARS-CoV-2. The Breast Health segment offers a comprehensive range of breast cancer care solutions, including 3D digital mammography systems, image analytics software, and minimally invasive breast biopsy guidance systems.

From a financial perspective, Hologic has demonstrated a strong track record of revenue growth, driven by its innovative product portfolio and strategic acquisitions. Key performance indicators (KPIs) such as revenue growth rate, gross margin, and operating margin are crucial in evaluating the companys financial health. With a market capitalization of $14.6 billion, Hologics financials indicate a stable and profitable business model.

To further analyze Hologics performance, we can examine additional KPIs, such as return on equity (ROE) of 11.44%, indicating a relatively stable return on shareholder investment. The companys forward price-to-earnings (P/E) ratio of 14.53 suggests a moderate valuation compared to its expected earnings growth. Furthermore, Hologics dividend yield and payout ratio can provide insights into its shareholder return strategy.

Overall, Hologics diversified product portfolio, strong financials, and commitment to innovation position the company for continued growth and success in the healthcare equipment industry.

HOLX Stock Overview

Market Cap in USD	15,064m
Sub-Industry	Health Care Equipment
IPO / Inception	1990-06-21

HOLX Stock Ratings

Growth Rating	-13.4%
Fundamental	70.5%
Dividend Rating	-
Return 12m vs S&P 500	-24.8%
Analyst Rating	3.45 of 5

HOLX Dividends

Currently no dividends paid

HOLX Growth Ratios

Growth Correlation 3m	16.5%
Growth Correlation 12m	-41.2%
Growth Correlation 5y	-12%
CAGR 5y	3.81%
CAGR/Max DD 3y (Calmar Ratio)	0.10
CAGR/Mean DD 3y (Pain Ratio)	0.25
Sharpe Ratio 12m	-0.52
Alpha	-26.05
Beta	0.627
Volatility	22.41%
Current Volume	2871.9k
Average Volume 20d	1569.9k
Stop Loss	67.7 (-3.1%)
Signal	0.82

Piotroski VR‑10 (Strict, 0-10) 6.0

Net Income (557.1m TTM) > 0 and > 6% of Revenue (6% = 242.3m TTM)

FCFTA 0.11 (>2.0%) and ΔFCFTA -0.30pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue 60.88% (prev 75.10%; Δ -14.22pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA 0.12 (>3.0%) and CFO 1.07b > Net Income 557.1m (YES >=105%, WARN >=100%)

Net Debt (787.3m) to EBITDA (1.01b) ratio: 0.78 <= 3.0 (WARN <= 3.5)

Current Ratio 3.55 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (225.5m) change vs 12m ago -4.65% (target <= -2.0% for YES)

Gross Margin 51.80% (prev 55.14%; Δ -3.34pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 45.65% (prev 44.85%; Δ 0.79pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio 6.15 (EBITDA TTM 1.01b / Interest Expense TTM 120.4m) >= 6 (WARN >= 3)

Altman Z'' 4.42

(A) 0.28 = (Total Current Assets 3.42b - Total Current Liabilities 962.5m) / Total Assets 8.81b

(B) 0.37 = Retained Earnings (Balance) 3.22b / Total Assets 8.81b

(D) 0.79 = Book Value of Equity 3.14b / Total Liabilities 3.96b

Total Rating: 4.42 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 70.51

1. Piotroski 6.0pt = 1.0

2. FCF Yield 6.23% = 3.11

3. FCF Margin 24.22% = 6.06

4. Debt/Equity 0.52 = 2.37

5. Debt/Ebitda 0.78 = 2.04

6. ROIC - WACC (= 1.07)% = 1.33

7. RoE 11.51% = 0.96

8. Rev. Trend 14.00% = 1.05

9. EPS Trend 51.83% = 2.59

What is the price of HOLX shares?

As of October 18, 2025, the stock is trading at USD 69.85 with a total of 2,871,914 shares traded.
Over the past week, the price has changed by +3.08%, over one month by +2.42%, over three months by +9.11% and over the past year by -13.20%.

Is Hologic a good stock to buy?

Partly, yes. Based on ValueRay´s Fundamental Analyses, Hologic (NASDAQ:HOLX) is currently (October 2025) ok to buy, but has to be watched. It has a ValueRay Fundamental Rating of 70.51 and therefor a somewhat positive outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of HOLX is around 62.42 USD . This means that HOLX is currently overvalued and has a potential downside of -10.64%.

Is HOLX a buy, sell or hold?

Hologic has received a consensus analysts rating of 3.45. Therefor, it is recommend to hold HOLX.

Strong Buy: 3
Buy: 3
Hold: 14
Sell: 0
Strong Sell: 0

What are the forecasts/targets for the HOLX price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	73.1	4.6%
Analysts Target Price	73.1	4.6%
ValueRay Target Price	68.8	-1.4%

Last update: 2025-10-09 02:25

HOLX Fundamental Data Overview

Market Cap USD = 15.06b (15.06b USD * 1.0 USD.USD)
P/E Trailing = 28.1037
P/E Forward = 14.9254
P/S = 3.7298
P/B = 3.1192
P/EG = 1.5076
Beta = 0.627
Revenue TTM = 4.04b USD
EBIT TTM = 740.2m USD
EBITDA TTM = 1.01b USD
Long Term Debt = 2.51b USD (from longTermDebt, last quarter)
Short Term Debt = 3.40m USD (from shortTermDebt, last quarter)
Debt = 2.52b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 787.3m USD (from netDebt column, last quarter)
Enterprise Value = 15.71b USD (15.06b + Debt 2.52b - CCE 1.88b)
Interest Coverage Ratio = 6.15 (Ebit TTM 740.2m / Interest Expense TTM 120.4m)
FCF Yield = 6.23% (FCF TTM 978.2m / Enterprise Value 15.71b)
FCF Margin = 24.22% (FCF TTM 978.2m / Revenue TTM 4.04b)
Net Margin = 13.79% (Net Income TTM 557.1m / Revenue TTM 4.04b)
Gross Margin = 51.80% ((Revenue TTM 4.04b - Cost of Revenue TTM 1.95b) / Revenue TTM)
Gross Margin QoQ = 56.32% (prev 38.00%)
Tobins Q-Ratio = 1.78 (Enterprise Value 15.71b / Total Assets 8.81b)
Interest Expense / Debt = 1.15% (Interest Expense 28.9m / Debt 2.52b)
Taxrate = 17.06% (40.1m / 235.0m)
NOPAT = 613.9m (EBIT 740.2m * (1 - 17.06%))
Current Ratio = 3.55 (Total Current Assets 3.42b / Total Current Liabilities 962.5m)
Debt / Equity = 0.52 (Debt 2.52b / totalStockholderEquity, last quarter 4.84b)
Debt / EBITDA = 0.78 (Net Debt 787.3m / EBITDA 1.01b)
Debt / FCF = 0.80 (Net Debt 787.3m / FCF TTM 978.2m)
Total Stockholder Equity = 4.84b (last 4 quarters mean from totalStockholderEquity)
RoA = 6.33% (Net Income 557.1m / Total Assets 8.81b)
RoE = 11.51% (Net Income TTM 557.1m / Total Stockholder Equity 4.84b)
RoCE = 10.07% (EBIT 740.2m / Capital Employed (Equity 4.84b + L.T.Debt 2.51b))
RoIC = 8.34% (NOPAT 613.9m / Invested Capital 7.36b)
WACC = 7.27% (E(15.06b)/V(17.59b) * Re(8.33%) + D(2.52b)/V(17.59b) * Rd(1.15%) * (1-Tc(0.17)))
Discount Rate = 8.33% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -3.12%
[DCF Debug] Terminal Value 76.58% ; FCFE base≈992.7m ; Y1≈950.1m ; Y5≈923.2m
Fair Price DCF = 70.21 (DCF Value 15.62b / Shares Outstanding 222.4m; 5y FCF grow -5.69% → 3.0% )
EPS Correlation: 51.83 | EPS CAGR: 10.53% | SUE: 1.53 | # QB: 1
Revenue Correlation: 14.00 | Revenue CAGR: 2.63% | SUE: 2.02 | # QB: 1

Additional Sources for HOLX Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle